Literature DB >> 11336466

Chemotherapy for advanced breast cancer: what influences oncologists' decision-making?

E A Grunfeld1, A J Ramirez, E J Maher, D Peach, T Young, I P Albery, M A Richards.   

Abstract

Chemotherapy is widely used in the management of patients with advanced breast cancer. However, a considerable proportion of patients experience toxic side effects without gaining benefit. This study aimed to elicit oncologists' views of the goals of chemotherapy for patients with advanced breast cancer and to elicit which factors are important in decisions to recommend chemotherapy to such patients. 30 oncologists underwent a semi-structured interview to examine their views of 5 goals of chemotherapy and of various disease, treatment and patient-related factors that might influence decisions to offer treatment. The clinicians also made decisions regarding treatment in relation to a hypothetical patient scenario under varying clinical conditions. Relief of symptoms and improvement of activity were rated as the most valuable and achievable goals of treatment. The patient's performance status, frailty and their wishes regarding treatment were the most important patient-related factors in determining decision-making. The most important disease/treatment-related factors were pace of the disease, previous poor response to chemotherapy, co-existing symptoms and concurrent medical conditions. The hypothetical scenario revealed that co-existing medical conditions, adverse previous response, increased age and depression would decrease the likelihood of recommending chemotherapy, whereas key symptoms (e.g. breathlessness) and the patient's goals would increase the likelihood. The findings suggest that British oncologists primarily aim to improve patients' physical function, although subjective factors, such as a patient's desire for anti-cancer treatment and their future goals, also influence decisions to offer treatment. Copyright 2001 Cancer Research Campaign http://www.bjcancer.com.

Entities:  

Mesh:

Year:  2001        PMID: 11336466      PMCID: PMC2363889          DOI: 10.1054/bjoc.2001.1733

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

Review 1.  Appropriate chemotherapy for palliating advanced cancer.

Authors:  R D Rubens; K E Towlson; A J Ramirez; S Coltart; M L Slevin; C Terrell; A R Timothy
Journal:  BMJ       Date:  1992-01-04

2.  The theory of decision making.

Authors:  W EDWARDS
Journal:  Psychol Bull       Date:  1954-07       Impact factor: 17.737

3.  Treatment strategies in advanced and metastatic cancer: differences in attitude between the USA, Canada and Europe.

Authors:  E J Maher; L Coia; G Duncan; P A Lawton
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

4.  Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer.

Authors:  P Geels; E Eisenhauer; A Bezjak; B Zee; A Day
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

5.  Prognosis and treatment decisions in patients with breast cancer without axillary node involvement.

Authors:  W L McGuire; A K Tandon; D C Allred; G C Chamness; P M Ravdin; G M Clark
Journal:  Cancer       Date:  1992-09-15       Impact factor: 6.860

6.  Ratings of the importance of quality of life variables: therapeutic implications for patients with metastatic breast cancer.

Authors:  H J Sutherland; G A Lockwood; N F Boyd
Journal:  J Clin Epidemiol       Date:  1990       Impact factor: 6.437

7.  Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public.

Authors:  M L Slevin; L Stubbs; H J Plant; P Wilson; W M Gregory; P J Armes; S M Downer
Journal:  BMJ       Date:  1990-06-02

8.  Variations in breast cancer treatment decisions and their impact in mounting trials.

Authors:  R B Deber; G G Thompson
Journal:  Control Clin Trials       Date:  1990-10

9.  Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.

Authors:  G Falkson; R Gelman; C I Falkson; J Glick; J Harris
Journal:  J Clin Oncol       Date:  1991-12       Impact factor: 44.544

10.  Decision making in advanced cancer of the head and neck: variation in the views of medical specialists.

Authors:  E J Maher; A F Jefferis
Journal:  J R Soc Med       Date:  1990-06       Impact factor: 18.000

View more
  13 in total

Review 1.  Effect of sex and gender on psychosocial aspects of prostate and breast cancer.

Authors:  A Kiss; S Meryn
Journal:  BMJ       Date:  2001-11-03

2.  Controversies on the management of clinical situations with low therapeutic effectiveness in oncology.

Authors:  José Expósito; Juan José Bretón; Carmen Domínguez; Joana Pons
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

3.  Antineoplastic therapy use in patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center: a simultaneous care model.

Authors:  David Hui; Ahmed Elsayem; Zhijun Li; Maxine De La Cruz; J Lynn Palmer; Eduardo Bruera
Journal:  Cancer       Date:  2010-04-15       Impact factor: 6.860

4.  Prospective Longitudinal Assessment of Health-related Quality of Life in Patients With Brain Metastases Undergoing Radiation Therapy.

Authors:  Mia Salans; Anthony Yip; Jeffrey Burkeen; Kevin X Liu; Euyhyun Lee; Tonya Pan-Weisz; Deborah Marshall; Susan G R McDuff; Yasamin Sharifzadeh; Yoseph Dalia; Parag Sanghvi; Daniel Simpson; Ronghui Xu; Carrie McDonald; Jona A Hattangadi-Gluth
Journal:  Am J Clin Oncol       Date:  2021-10-01       Impact factor: 2.787

5.  Factors affecting receipt of chemotherapy in women with breast cancer.

Authors:  Libby Morimoto; Jenna Coalson; Fionna Mowat; Cynthia O'Malley
Journal:  Int J Womens Health       Date:  2010-08-09

6.  Targeted agent use in cancer patients at the end of life.

Authors:  David Hui; Meghan Sri Karuturi; Kimberson Cochien Tanco; Jung Hye Kwon; Sun-Hyun Kim; Tao Zhang; Jung Hun Kang; Gary Chisholm; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2012-12-01       Impact factor: 3.612

7.  Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study.

Authors:  Katrin M Sjoquist; Michael L Friedlander; Rachel L O'Connell; Merryn Voysey; Madeleine T King; Martin R Stockler; Amit M Oza; Kim Gillies; Julie K Martyn; Phyllis N Butow
Journal:  Oncologist       Date:  2013-10-09

8.  Patients' understanding of treatment goals and disease course and their relationship with optimism, hope, and quality of life: a preliminary study among advanced breast cancer outpatients before receiving palliative treatment.

Authors:  Cem Soylu; Taner Babacan; Ali R Sever; Kadri Altundag
Journal:  Support Care Cancer       Date:  2016-03-22       Impact factor: 3.603

9.  Letrozole in advanced breast cancer: the PO25 trial.

Authors:  Henning T Mouridsen
Journal:  Breast Cancer Res Treat       Date:  2007-02-27       Impact factor: 4.872

Review 10.  The patient experience.

Authors:  Nadia Harbeck; Renate Haidinger
Journal:  Breast Cancer Res Treat       Date:  2007-10-03       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.